James X. Sun
James X. Sun
Unknown affiliation
Verified email at
Cited by
Cited by
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ...
Genome medicine 9 (1), 1-14, 2017
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ...
Nature biotechnology 31 (11), 1023-1031, 2013
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ...
The lancet oncology 18 (1), 75-87, 2017
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast CancerESR1-Activating Mutations in Advanced Breast Cancer
R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ...
Clinical cancer research 20 (7), 1757-1767, 2014
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeHybrid Capture–Based NGS and Response to Anti–PD-1
DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ...
Cancer immunology research 4 (11), 959-967, 2016
A direct characterization of human mutation based on microsatellites
JX Sun, A Helgason, G Masson, SS Ebenesersdóttir, H Li, S Mallick, ...
Nature Genetics, 2012
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaSecondary Mutations …
O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ...
Cancer discovery 7 (9), 984-998, 2017
Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer
JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ...
Journal of Clinical Oncology 35 (23), 2624, 2017
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaBRCA Reversion …
KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ...
Cancer discovery 9 (2), 210-219, 2019
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated …
AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ...
Gynecologic oncology 147 (2), 267-275, 2017
Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
DR Spigel, AB Schrock, D Fabrizio, GM Frampton, J Sun, J He, K Gowen, ...
Journal of Clinical Oncology, 2016
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ...
Journal of gastrointestinal oncology 9 (4), 610, 2018
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
JNCI: Journal of the National Cancer Institute 109 (12), 2017
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
JX Sun, Y He, E Sanford, M Montesion, GM Frampton, S Vignot, JC Soria, ...
PLoS computational biology 14 (2), e1005965, 2018
Comprehensive genomic profiling of 282 pediatric low‐and high‐grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures
A Johnson, E Severson, L Gay, JA Vergilio, J Elvin, J Suh, S Daniel, ...
The oncologist 22 (12), 1478-1490, 2017
Genomic profiling of small-bowel adenocarcinoma
AB Schrock, CE Devoe, R McWilliams, J Sun, T Aparicio, PJ Stephens, ...
JAMA oncology 3 (11), 1546-1553, 2017
Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene MutationsERBB2 Mutations in Lobular Breast Cancer
JS Ross, K Wang, CE Sheehan, AB Boguniewicz, G Otto, SR Downing, ...
Clinical cancer research 19 (10), 2668-2676, 2013
A signal abnormality index for arterial blood pressure waveforms
JX Sun, AT Reisner, RG Mark
2006 Computers in Cardiology, 13-16, 2006
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
JS Ross, M Fakih, SM Ali, JA Elvin, AB Schrock, J Suh, JA Vergilio, ...
Cancer 124 (7), 1358-1373, 2018
The system can't perform the operation now. Try again later.
Articles 1–20